Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for the diagnosis of heart disease. Through its AI-empowered solutions, Cleerly supports comprehensive phenotyping of coronary artery disease, through its evaluation of advanced non-invasive CT imaging. Cleerly’s approach is grounded in nearly 20 years of science from landmark multi-center clinical trials. Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.
Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for the diagnosis of heart disease. Through its AI-empowered solutions, Cleerly supports comprehensive phenotyping of coronary artery disease, through its evaluation of advanced non-invasive CT imaging. Cleerly’s approach is grounded in nearly 20 years of science from landmark multi-center clinical trials. Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.
TL;DR
What: AI-enabled analysis of coronary CT angiography (CCTA) to quantify plaque, stenosis, and likelihood of vessel-level ischemia
Mission: Eliminate heart attacks by creating a new standard of care for heart disease
Regulatory / product milestone: FDA-cleared software (Cleerly ISCHEMIA 510(k) clearance announced Jan 2024)
Recent funding: $106M Series C extension led by Insight Partners (Dec 4, 2024)
Total funding (reported): $417.8M (reported)
James K. Min, MD (founder; company founded 2017)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Non-invasive diagnosis and phenotyping of coronary artery disease using coronary CT angiography
Founded
2017
Industry
Medical Equipment Manufacturing
Funding Track Record
43,000,000
223,000,000
106,000,000
Battery Ventures and existing investors participated
Investor Signal
“Backed by late-stage investors including Insight Partners, Battery Ventures, T. Rowe Price, Fidelity, and Vensana Capital”